Amid a backlash against foreign investors, some executives are banned from leaving the country
The Camry, last overhauled for the 2011 model year, just got another face-lift
Laws require companies to pay state taxes on sheltered profits
Financial filings reveal the pay package Henrique de Castro received upon exit from the company.
Wal-Mart's new money transfers shows how the retailer can use its reach to push down costs
Skipping Rocks Lab develops a green alternative to all that plastic
Alessandro Borgognone wooed Japanese chef Daisuke Nakazawa to open the four-star New York eatery
Administrators quashed their food delivery service. Now they're focusing on other colleges
Prices are low, but there’s plenty of red tape
By Pete Engardio
For nearly two decades, America's life sciences industry has benefited from a Chinese brain drain. Since 1985 some 10,000 mainlanders have earned biomedicine PhDs in the U.S.—and the vast majority stayed to work at U.S. pharmaceutical companies and research universities. Now some of China's brightest brains are returning home to start drug-research companies, run university programs, and establish operations for multinationals.
China's gain is not necessarily America's loss, however. Most of these "sea turtles," as the returnees are known, are building strategic tieups with U.S. drugmakers that could expand their pipelines of new drugs, speed up development time, reduce R&D costs—and gain inroads to China's rapidly growing drug market. Others are founding U.S. companies with China operations.
Following are some of the most influential sea turtles.